BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Rating of “Moderate Buy” from Analysts

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has been given a consensus rating of “Moderate Buy” by the fourteen brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $365.7857.

A number of brokerages have weighed in on ONC. Barclays initiated coverage on BeOne Medicines in a report on Thursday, September 18th. They issued an “overweight” rating and a $385.00 target price for the company. JPMorgan Chase & Co. lifted their price objective on shares of BeOne Medicines from $345.00 to $385.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 3rd. Royal Bank Of Canada upped their price objective on shares of BeOne Medicines from $395.00 to $408.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Finally, Citigroup raised their target price on BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research note on Monday, November 10th.

Insider Activity

In other news, CEO John Oyler sold 27,803 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $325.71, for a total transaction of $9,055,715.13. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Lai Wang sold 5,000 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $350.06, for a total value of $1,750,300.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 81,094 shares of company stock valued at $27,929,161. Corporate insiders own 6.62% of the company’s stock.

Institutional Investors Weigh In On BeOne Medicines

Institutional investors and hedge funds have recently made changes to their positions in the business. Parallel Advisors LLC bought a new position in BeOne Medicines in the 2nd quarter valued at about $59,000. Aaron Wealth Advisors LLC purchased a new stake in shares of BeOne Medicines in the second quarter worth approximately $200,000. Farther Finance Advisors LLC bought a new position in shares of BeOne Medicines in the second quarter valued at approximately $39,000. Avanza Fonder AB purchased a new position in shares of BeOne Medicines during the second quarter valued at approximately $199,000. Finally, Public Employees Retirement System of Ohio bought a new stake in BeOne Medicines during the second quarter worth $3,491,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Stock Performance

ONC stock opened at $331.40 on Friday. The firm has a market cap of $39.28 billion, a PE ratio of 649.80 and a beta of 0.45. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. The stock has a 50-day moving average price of $332.91 and a 200-day moving average price of $301.64. BeOne Medicines has a 1-year low of $170.99 and a 1-year high of $385.22.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.